Clinical Trial

A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 5, 2025 (before its estimated April 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
A randomized, double-blind, placebo-controlled Phase IIa clinical study to evaluate the safety and efficacy of GST-HG131 tablets in patients with chronic hepatitis B
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-02-14.
Trial Details
NCT Number NCT06263959
Lead Sponsor Fujian Akeylink Biotechnology Co., Ltd.
Conditions Chronic Hepatitis B
Enrollment 45 participants
Start Date 2023-12-26
Primary Completion 2025-04-01 (estimated)
Study Completion 2025-05-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-05